Pathology/Immunology Core

佛罗里达大学的分子病理学和免疫学核心目前协助多个 参与旨在提高对1型糖尿病发病机制的理解的项目的研究人员 糖尿病，以及开发能够逆转和/或预防该疾病的药剂。 具体来说，核心支持这些调查进行病理和免疫分析 表征宿主的免疫系统和细胞/组织反应，包括涉及治疗的那些 目前正在实验和临床前研究中提出或使用。这一目标已经并将继续是 通过执行三个具体目标来实现：1）在以下背景下确定组织形态： 组织病理学，以评价给药部位、剂量和治疗的治疗效果 持续时间2)确定治疗在糖尿病鼠模型中的潜在有益作用; 评估胰腺以及与1型糖尿病相关的其他器官。3)进行免疫学检查 在动物模型和人类受试者中的评价，其表征与体液和免疫相关的方面， 细胞免疫反应，以及提供1型糖尿病的遗传易感性。形态 研究是至关重要的，以评估是否一个给定的项目的干预成功地改善了亲， 胰腺、淋巴结、脾脏和其他器官内的炎症环境，并确定 任何干预诱导急性炎症或细胞毒性的程度。集中统一 形态学研究以及组织病理学和毒理学决定因素的标准化， 细胞反应的严格评估。程序包括石蜡和冷冻的标准组织学 材料、特殊染色、组织化学、免疫组化和免疫荧光。方面 分析人类样本，核心实验室将建立在超过二十年的经验， 评估1型或1型风险增加患者血清中自身抗体存在的术语 糖尿病，以及通过HLA分型确定疾病的遗传易感性。在 除了提供用于保证治疗安全性和改进的机制的关键要素之外， 理解，核心应提供信息，将提高临床前的可行性和有效性， 预防或逆转1型糖尿病的试验。

The Molecular Pathology and Immunology Core of the University of Florida currently assists multiple investigators participating in Projects aimed at an improved understanding of the pathogenesis of type 1 diabetes, as well as the development of agents capable of reversing and/or preventing the disease. Specifically, the Core supports these investigations by performing pathological and immunological analyses that characterize the host's immune system and cell/tissue response, including those involving treatments proposed or currently used in experimental and preclinical studies. This goal has and will continue to be accomplished by performance of three specific aims: 1) Determine tissue morphology in the context of histopathology in order to evaluate treatment effects with respect to administration site, dose, and treatment duration. 2) Determine the potential beneficial effects of treatments in murine models of diabetes; with assessment of the pancreas as well other organs related to type 1 diabetes. 3) Perform immunologic evaluations in animal models and human subjects that characterize aspects related to the humoral and cellular immune response, as well as providing genetic susceptibility to type 1 diabetes. The morphological studies are vital in order to evaluate whether a given Project's intervention successfully ameliorates the pro- inflammatory environment within the pancreas, lymph node, spleen, and other organs and to determine the extent to which any intervention induces acute inflammation or cytotoxicity. Centralization of the morphological studies, and standardization of the histopathological and toxicological determinants, enables rigorous assessment of cellular responses. Procedures include standard histology on paraffin and frozen materials, special stains, histochemistry, immunohistochemistry, and immunofluorescence. In terms of analysis of human samples, the Core laboratory will build upon more that two decades of experience in terms of evaluating for the presence of autoantibodies in serum of patients with or at increased-risk of type 1 diabetes, as well as determining the genetic susceptibility for the disease by performance of HLA typing. In addition to providing a critical element for assurance of therapeutic safety and improved mechanistic understanding, the Core should provide information that will enhance the feasibility and efficacy of preclinical trials to prevent or reverse type 1 diabetes.